Many of the major diseases, including cardiovascular disease, are widely recognized as inflammatory diseases. MCP-1 (monocyte chemotactic protein-1) plays a critical role in the development of cardiovascular diseases. MCP-1, by its chemotactic activity, causes diapedesis of monocytes from the lumen to the subendothelial space where they become foam cells, initiating fatty streak formation that leads to atherosclerotic plaque formation. Inflammatory macrophages probably play a role in plaque rupture and the resulting ischaemic episode as well as restenosis after angioplasty. There is strong evidence that MCP-1 plays a major role in myocarditis, ischaemia/reperfusion injury in the heart and in transplant rejection. MCP-1 also plays a role in cardiac repair and manifests protective effects under certain conditions. Such protective effects may be due to the induction of protective ER (endoplasmic reticulum) stress chaperones by MCP-1. Under sustained ER stress caused by chronic exposure to MCP-1, the protection would break down resulting in the development of heart failure. MCP-1 is also involved in ischaemic angiogenesis. The recent advances in our understanding of the molecular mechanisms that might be involved in the roles that MCP-1 plays in cardiovascular disease are reviewed. The gene expression changes induced by the signalling events triggered by MCP-1 binding to its receptor include the induction of a novel zinc-finger protein called MCPIP (MCP-1-induced protein), which plays critical roles in the development of the pathophysiology caused by MCP-1 production. The role of the MCP-1/CCR2 (CC chemokine receptor 2) system in diabetes, which is a major risk factor for cardiovascular diseases, is also reviewed briefly. MCP-1/CCR2- and/or MCPIP-targeted therapeutic approaches to intervene in inflammatory diseases, including cardiovascular diseases, may be feasible.
Skip Nav Destination
Article navigation
August 2009
-
Cover Image
Cover Image
- PDF Icon PDF LinkTable of Contents
Review Article|
July 02 2009
Role of MCP-1 in cardiovascular disease: molecular mechanisms and clinical implications
Jianli Niu;
Jianli Niu
1Burnett School of Biomedical Sciences, College of Medicine, University of Central Florida, 4000 Central FL Blvd, Orlando, FL 32816, U.S.A.
Search for other works by this author on:
Pappachan E. Kolattukudy
1Burnett School of Biomedical Sciences, College of Medicine, University of Central Florida, 4000 Central FL Blvd, Orlando, FL 32816, U.S.A.
Correspondence: Dr Pappachan E. Kolattukudy (email [email protected]).
Search for other works by this author on:
Publisher: Portland Press Ltd
Received:
November 07 2008
Revision Received:
January 22 2009
Accepted:
February 24 2009
Online ISSN: 1470-8736
Print ISSN: 0143-5221
© The Authors Journal compilation © 2009 Biochemical Society
2009
Clin Sci (Lond) (2009) 117 (3): 95–109.
Article history
Received:
November 07 2008
Revision Received:
January 22 2009
Accepted:
February 24 2009
Citation
Jianli Niu, Pappachan E. Kolattukudy; Role of MCP-1 in cardiovascular disease: molecular mechanisms and clinical implications. Clin Sci (Lond) 1 August 2009; 117 (3): 95–109. doi: https://doi.org/10.1042/CS20080581
Download citation file:
Sign in
Don't already have an account? Register
Sign in to your personal account
You could not be signed in. Please check your email address / username and password and try again.
Could not validate captcha. Please try again.
Biochemical Society Member Sign in
Sign InSign in via your Institution
Sign in via your InstitutionGet Access To This Article
Open Access for all
We offer compliant routes for all authors from 2025. With library support, there will be no author nor reader charges in 5 journals. Check here |
![]() |